Author:
Yamamoto Gaku,Asahina Hajime,Honjo Osamu,Sumi Toshiyuki,Nakamura Atsushi,Ito Kenichiro,Kikuchi Hajime,Hommura Fumihiro,Honda Ryoichi,Yokoo Keiki,Fujita Yuka,Oizumi Satoshi,Morita Ryo,Ikezawa Yasuyuki,Tanaka Hisashi,Kimura Nozomu,Sasaki Takaaki,Sukoh Noriaki,Takashina Taichi,Harada Toshiyuki,Dosaka-Akita Hirotoshi,Isobe Hiroshi,Yamamoto Gaku,Asahina Hajime,Honjo Osamu,Sumi Toshiyuki,Nakamura Atsushi,Ito Kenichiro,Isobe Hiroshi,Kikuchi Hajime,Hommura Fumihiro,Honda Ryoichi,Yokoo Keiki,Fujita Yuka,Oizumi Satoshi,Morita Ryo,Ikezawa Yasuyuki,Tanaka Hisashi,Kimura Nozomu,Sasaki Takaaki,Sukoh Noriaki,Takashina Taichi,Harada Toshiyuki,Akita Hirotoshi,
Abstract
AbstractOsimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1–73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9–23.9) months. The median overall survival was not reached (95% confidence interval 24.6–not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 4, 1568 (2018).
2. Dearden, S., Stevens, J., Wu, Y. L. & Blowers, D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 24, 2371–2376 (2013).
3. Midha, A., Dearden, S. & McCormack, R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 5, 2892–2911 (2015).
4. Pallis, A. G. et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann. Oncol. 25, 1270–1283 (2014).
5. Marur, S. et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Semin. Oncol. 45, 220–225 (2018).